We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Idenix Stumbles in Hep C Race; FDA Wants More Data on Oral Drug Candidate
Idenix Stumbles in Hep C Race; FDA Wants More Data on Oral Drug Candidate
June 21, 2013
Idenix, a small drugmaker racing to develop the first and most effective all-oral hepatitis C drug regimen, has been asked by the FDA to submit additional preclinical safety data for its lead uridine nucleotide candidate IDX20963.